RT Journal Article
T1 Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
A1 Almeida, Antonio M
A1 Prebet, Thomas
A1 Itzykson, Raphael
A1 Ramos, Fernando
A1 Al-Ali, Haifa
A1 Shammo, Jamile
A1 Pinto, Ricardo
A1 Maurillo, Luca
A1 Wetzel, Jaime
A1 Musto, Pellegrino
A1 Van De Loosdrecht, Arjan A
A1 Costa, Maria Joao
A1 Esteves, Susana
A1 Burgstaller, Sonja
A1 Stauder, Reinhard
A1 Autzinger, Eva M
A1 Lang, Alois
A1 Krippl, Peter
A1 Geissler, Dietmar
A1 Falantes, Jose Francisco
A1 Pedro, Carmen
A1 Bargay, Joan
A1 Deben, Guillermo
A1 Garrido, Ana
A1 Bonanad, Santiago
A1 Diez-Campelo, Maria
A1 Thepot, Sylvain
A1 Ades, Lionel
A1 Sperr, Wolfgang R
A1 Valent, Peter
A1 Fenaux, Pierre
A1 Sekeres, Mikkael A
A1 Greil, Richard
A1 Pleyer, Lisa
K1 acute erythroleukemia
K1 azacitidine
K1 decitabine
AB Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.
YR 2017
FD 2017-04-14
LK http://hdl.handle.net/10668/11108
UL http://hdl.handle.net/10668/11108
LA en
DS RISalud
RD Apr 14, 2025